Filing Flows › Geron (GERN) › Guidance & outlook

Geron (GERN) guidance and outlook

Geron (GERN) lowered its guidance on Nov 4, 2026: Operating expenses $220M–$230M for FY2026. Geron's 10-Q filed Nov 4, 2026 makes 28 forward-looking statements.

Guidance and outlook

Latest guidance

From the earnings release filed Nov 4, 2026 (8-K on EDGAR).

Forward-looking statements, 10-Q filed Nov 4, 2026

• We have initiated a gated commercial launch in targeted European markets, with a commercialization partner and a related contracted sales force, with availability expected in Germany by the end of 2026 and in France in 2027.
• In addition to lower-risk MDS, we are developing imetelstat for the treatment of other myeloid hematologic malignancies, but there can be no assurance that we will obtain and maintain the necessary regulatory approvals to market RYTELO for any additional indications.
• Given the discontinuation of the Phase 3 IMpactMF trial, we will be unable to pursue any regulatory approvals for the relapsed/refractory MF indication and we will otherwise not receive any return on, or recoup our investment in the relapsed/refractory MF indication.
• Moreover, the development of imetelstat for the treatment of other myeloid hematologic malignancies is in the early stages and we do not expect to receive any regulatory approvals to market RYTELO for any additional indications for a number of years, if ever.
• Accordingly, we will remain wholly dependent on the commercialization of RYTELO in lower-risk MDS for the foreseeable future.
• If we are unable to realize the expected operational efficiencies and cost savings from the restructuring, our operating results and financial condition could be adversely affected.
• Our commercial execution is focused on targeted engagement with high-volume accounts that treat earlier-line patients, investment in non-personal promotion and third-party education to further consistent, high-quality messaging across multiple touchpoints, and cross-functional execution of effective account management.
• However, our strategy to drive sales growth and our ongoing commercialization efforts have not to date achieved and may not in the future achieve meaningful sales growth, which may require us to, among others, further adjust or amend our commercialization strategy and plans and incur significant expenses, and there can be no assurance that we will be able to grow RYTELO net product revenue in future periods.
• In particular, our strategy may not drive new patient starts across the breadth of the eligible patient population in RYTELO's approved indication, particularly across appropriate second-line patients in RYTELO's approved indication, in a timely manner or at all, or the duration of therapy could be shorter than we expect, each of which would limit RYTELO’s growth potential and could preclude or delay our ability…
• In addition, in an effort to expand its indications of use, we are also developing RYTELO for the treatment of several myeloid hematologic malignancies that will continue to require additional time and significant investment in clinical trials to complete.
• As a result, we will be unable to expand RYTELO’s indication to use to the relapsed/refractory MF indication and we will otherwise not receive any return on or recoup our investment in the relapsed/refractory MF indication.
• We also expect to continue to seek regulatory approvals of RYTELO in lower-risk MDS in jurisdictions outside of the U.S., such as our recent marketing authorization in the EU, and to establish arrangements with third parties to assist us in the commercialization of RYTELO in such jurisdictions.

Geron's latest quarter

Questions

Did Geron raise or lower its guidance?

Geron (GERN) lowered its guidance on Nov 4, 2026: Operating expenses $220M–$230M for FY2026.

What does Geron expect?

We have initiated a gated commercial launch in targeted European markets, with a commercialization partner and a related contracted sales force, with availability expected in Germany by the end of 2026 and in France in 2027. In addition to lower-risk MDS, we are developing imetelstat for the treatment of other myeloid hematologic malignancies, but there can be no assurance that we will obtain and maintain the necessary regulatory approvals to market RYTELO for any additional indications. Given the discontinuation of the Phase 3 IMpactMF trial, we will be unable to pursue any regulatory approva

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.